Doctors reduced opioid prescriptions after learning a patient overdosed
Will clinicians become more careful in prescribing opioids if they are made of aware of the risks of these drugs […]
Drug shortages and price hikes have become a critical issue in the health care industry. A recent example of this […] Getting wisdom teeth removed may be a rite of passage for many teens and young adults, but the opioid painkiller […] July 30, 2018 — The U.S. Food and Drug Administration today approved Azedra (iobenguane I 131) injection for intravenous use […] KENILWORTH, N.J.–(BUSINESS WIRE)–July 24, 2018 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced […] TOKYO and CAMBRIDGE, Mass., July 25, 2018 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and […] SOUTH SAN FRANCISCO, Calif., July 18, 2018 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on […] The U.S. Food and Drug Administration issued a voluntary recall of several medications that contain the active ingredient valsartan, which […] July 16, 2018 — Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, […] The overdose-reversing drug naloxone saves thousands of lives each year and is more widely available today than ever. So why […]Medications
Potential solutions to drug shortages and the lack of competition in generic medicines
Unwise opioids for wisdom teeth: Study shows link to long-term use in teens and young adults
FDA Approves Azedra
Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine
Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018
Catalyst Biosciences Announces Positive Interim Data from a Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors
FDA recalls heart medication valsartan, citing cancer concerns
Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy Fidanacogene Elaparvovec
Naloxone remains controversial to some, but here’s why it shouldn’t be